Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
Status:
Completed
Trial end date:
2019-04-28
Target enrollment:
Participant gender:
Summary
This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission
tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of
clinically-meaningful cognitive decline due to AD after 18 months. All scans are acquired
from cohorts of a previously completed study, I8D-MC-AZES (NCT02245737, lanabecestat, Eli
Lilly and Company sponsor).